Bal Pharma launches BALflu – generic of Covid-19 drug Favipiravir in India

Bal Pharma Ltd has launched its generic of the Covid-19 drug Favipiravir under the brand name BALflu in India.

Favipiravir has been used as an anti viral drug for the treatment of patients having mild to moderate Covid-19 infection. Its formulation is available in tablets form with a strength of 400 mg.

The Covid-19 drug works by blocking and terminating viral protein synthesis and by inducing lethal metagenesis of influenza virus.

Favipiravir was approved by the Drug Controller General of India (DCGI) for emergency use for Covid treatment with a recommended dosage of 1800 mg on the first day after which 800 mg has to be taken from day 2 to 14.

Shailesh Siroya – Managing Director of Bal Pharma said that the BALflu has the efficacy to clear the novel coronavirus faster by 28.7%. BALflu cost is INR 85 per tablet and can be purchased as a prescription drug.